Cargills (Ceylon) PLC (COSE:CARG.N0000)
Sri Lanka · Delayed Price · Currency is LKR 615.00
+8.25 (1.36%)
At close: Aug 7, 2025
Theseus Pharmaceuticals Income Statement
Financials in millions LKR. Fiscal year is April - March.
Millions LKR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| 241,840 | 223,440 | 195,618 | 136,692 | 112,607 | Upgrade | |
Revenue Growth (YoY) | 8.23% | 14.22% | 43.11% | 21.39% | 5.19% | Upgrade |
Cost of Revenue | 214,083 | 198,688 | 172,948 | 121,119 | 100,148 | Upgrade |
Gross Profit | 27,756 | 24,752 | 22,670 | 15,573 | 12,459 | Upgrade |
Selling, General & Admin | 15,636 | 13,523 | 11,243 | 8,683 | 6,499 | Upgrade |
Other Operating Expenses | -3,041 | -2,177 | -2,324 | -2,162 | -1,260 | Upgrade |
Operating Expenses | 12,595 | 11,347 | 8,919 | 6,520 | 5,240 | Upgrade |
Operating Income | 15,161 | 13,406 | 13,751 | 9,052 | 7,219 | Upgrade |
Interest Expense | -4,899 | -7,197 | -6,573 | -2,982 | -2,720 | Upgrade |
Interest & Investment Income | 737.01 | 1,964 | 787.2 | 244.1 | 184.28 | Upgrade |
Earnings From Equity Investments | 232.64 | 52.53 | 193.69 | -114.18 | -297.95 | Upgrade |
Currency Exchange Gain (Loss) | 2.36 | 2.06 | 55.62 | -515.9 | 21.22 | Upgrade |
EBT Excluding Unusual Items | 11,234 | 8,227 | 8,214 | 5,685 | 4,407 | Upgrade |
Gain (Loss) on Sale of Assets | 10.15 | 1.2 | 1.5 | 4.28 | 66.42 | Upgrade |
Asset Writedown | 585.16 | 1,018 | 300.78 | 129.46 | 54.63 | Upgrade |
Pretax Income | 11,829 | 9,246 | 8,517 | 5,818 | 4,528 | Upgrade |
Income Tax Expense | 4,559 | 3,310 | 3,136 | 1,280 | 1,044 | Upgrade |
Earnings From Continuing Operations | 7,270 | 5,936 | 5,381 | 4,539 | 3,484 | Upgrade |
Net Income to Company | 7,270 | 5,936 | 5,381 | 4,539 | 3,484 | Upgrade |
Minority Interest in Earnings | -48.21 | -49.33 | -14.84 | 4.32 | -2.65 | Upgrade |
Net Income | 7,222 | 5,887 | 5,366 | 4,543 | 3,481 | Upgrade |
Net Income to Common | 7,222 | 5,887 | 5,366 | 4,543 | 3,481 | Upgrade |
Net Income Growth | 22.68% | 9.71% | 18.12% | 30.51% | 29.30% | Upgrade |
Shares Outstanding (Basic) | 258 | 258 | 258 | 258 | 258 | Upgrade |
Shares Outstanding (Diluted) | 258 | 258 | 258 | 258 | 258 | Upgrade |
Shares Change (YoY) | - | - | - | - | 0.13% | Upgrade |
EPS (Basic) | 28.03 | 22.85 | 20.82 | 17.63 | 13.51 | Upgrade |
EPS (Diluted) | 28.03 | 22.85 | 20.82 | 17.63 | 13.51 | Upgrade |
EPS Growth | 22.68% | 9.73% | 18.09% | 30.50% | 29.15% | Upgrade |
Free Cash Flow | 9,388 | 6,904 | -3,310 | 6,573 | 5,328 | Upgrade |
Free Cash Flow Per Share | 36.43 | 26.80 | -12.84 | 25.51 | 20.68 | Upgrade |
Dividend Per Share | 16.500 | 15.000 | 12.000 | 7.000 | 6.000 | Upgrade |
Dividend Growth | 10.00% | 25.00% | 71.43% | 16.67% | 17.65% | Upgrade |
Gross Margin | 11.48% | 11.08% | 11.59% | 11.39% | 11.06% | Upgrade |
Operating Margin | 6.27% | 6.00% | 7.03% | 6.62% | 6.41% | Upgrade |
Profit Margin | 2.99% | 2.63% | 2.74% | 3.32% | 3.09% | Upgrade |
Free Cash Flow Margin | 3.88% | 3.09% | -1.69% | 4.81% | 4.73% | Upgrade |
EBITDA | 19,935 | 17,966 | 17,695 | 12,528 | 10,188 | Upgrade |
EBITDA Margin | 8.24% | 8.04% | 9.05% | 9.16% | 9.05% | Upgrade |
D&A For EBITDA | 4,773 | 4,561 | 3,945 | 3,476 | 2,969 | Upgrade |
EBIT | 15,161 | 13,406 | 13,751 | 9,052 | 7,219 | Upgrade |
EBIT Margin | 6.27% | 6.00% | 7.03% | 6.62% | 6.41% | Upgrade |
Effective Tax Rate | 38.54% | 35.80% | 36.82% | 21.99% | 23.06% | Upgrade |
Updated Feb 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.